Posted by Michael Wonder on 08 Jan 2017
Agenda for 11 January 2017 TC meeting
6 January 2017 - HAS has posted the agenda for the first Transparency Commission meeting for 2017.
The Transparency Commission will consider the reimbursement of:
- Obinutuzumab (Gazyvaro)
- Lenalidomide (Revlimid)
- Idarubicin hydrochloride (Zavedos)
- Adalimumab (Humira)
- Budesonide (Cortiment)
